Clinical Trials Browser

Phase 1/2 × Colorectal Cancer Metastatic × sintilimab × Clear all

NCT04940546 2024-12-03

Neoadjuvant Safety of Sintilimab + XELOX + Bevacizumab in PMMR/MSS CRLM Patients

Phase 1/2 Active not recruiting

Gastrointestinal

Colorectal Cancer Metastatic